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Introduction: In the phase I and II trials, the dose-limiting toxicities
of pemetrexed included neutropenia, thrombocytopenia, and fatigue.
Grade 3 bilateral peripheral edema that resembled cellulitis was not
commonly described.
Methods: Since 2009, the Thoracic Oncology Service at Memorial
Sloan Kettering Cancer Center has identified 14 patients who de-
veloped bilateral peripheral edema and erythema of the lower
extremities while receiving pemetrexed chemotherapy. During this
time, 489 patients with thoracic malignancy have been treated with
pemetrexed.
Results: There were seven men and seven women. Average age was
72 years. All patients had stage IV adenocarcinoma of the lung. The
edema presented at a median of eight doses (range, 3–23 doses.)
Other causative factors such as deep vein thrombosis, renal insuffi-
ciency, and congestive heart failure were excluded. Thirteen of the
14 patients required the drug to be stopped or dose lowered.
Conclusion: We have collected 14 cases with lung adenocarcinoma
treated with pemetrexed who developed bilateral lower extremity
edema and erythema, a condition rarely described. In all cases,
symptoms resolved with discontinuation or dose reduction of the
drug. Patients who received corticosteroids showed improvement in
their symptoms.
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Pemetrexed is a folate analog that inhibits thymidylatesynthase, dihydrofolate reductase, and glycinamide ribo-
nucleotide formyl transferase.1 Pemetrexed has activity in
many malignancies, including non-small cell lung cancer
(NSCLC), colorectal cancer, pancreatic cancer, breast cancer,
and head and neck cancer.1 It is approved by the Food and
Drug Administration for first-line treatment in combination
with cisplatin of malignant pleural mesothelioma and ad-
vanced nonsquamous NSCLC, for second-line treatment of
advanced nonsquamous NSCLC, and as maintenance ther-
apy in patients with metastatic nonsquamous NSCLC
whose disease has not progressed after four cycles of
platinum-based first-line chemotherapy. In phase I and II
trials, the dose-limiting toxicities included neutropenia,
thrombocytopenia, and fatigue.2,3
In the phase III trial that compared docetaxel with
pemetrexed, the incidence of all grades of peripheral edema
was 5% in the pemetrexed group. Grade 3/4 peripheral edema
was not described. There is limited information describing
peripheral edema. In a case series, seven patients were iden-
tified as having developed fluid retention. In that series, other
causes of edema were excluded. Clinically, they presented
with mild to moderate edema, mostly in the periorbital area.
One patient developed severe, grade 3 edema with pleural
effusions that required thoracentesis. The pleural fluid was an
exudate without malignant cells and it resolved with discon-
tinuation of the pemetrexed. An additional patient had com-
plete resolution of the edema when pemetrexed was stopped
because of progression of disease.4 There was an additional
case report in a 56-year-old man who received 1000 mg/m2
and developed palpebral edema after the second cycle on day
8. Other causes were excluded. It subsequently improved 6
days after treatment with 8 mg of dexamethasone. The edema
recurred with each treatment.5
In this series, we describe peripheral edema that ranges
in severity from ankle swelling to pitting edema with over-
lying skin erythema. Clinically, it can be mistaken for cellu-
litis; however, it is often bilateral. The development of edema
can often be secondary to multiple causative factors including
deep vein thrombosis (DVT), cellulitis, heart, renal, or liver
failure, all of which have been excluded in our patients.
PATIENTS AND METHODS
Since 2009, the Thoracic Oncology Service at Memo-
rial Sloan Kettering Cancer Center has identified 14 patients
who developed peripheral edema and erythema of the bilat-
eral lower extremities while receiving pemetrexed chemo-
therapy. During this time, 489 patients with thoracic malig-
nancies have been treated with pemetrexed. Most received
500 mg/m2 every 3 weeks. Patients routinely received six
doses of dexamethasone 4 mg orally, twice daily, the day
before, of, and after treatment.
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Peripheral edema was graded according to the National
Cancer Institute-Cancer Therapy Evaluation Program, Common
Toxicity Criteria, version 3: grade 1 is asymptomatic and re-
quires no therapy, grade 2 is symptomatic and requires some
therapy, grade 3 is symptomatic edema that limits function and
is unresponsive to therapy or requires drug discontinuation, and
grade 4 is defined by anasarca.
SELECTED CASES
Case 1
A 67-year-old man with metastatic adenocarcinoma of
the lung was treated with 500 mg/m2 pemetrexed every 3
weeks. After his 21st dose, he developed grade 2 bilateral
lower extremity edema and erythema. There were no other
changes on his physical examination. Laboratory data re-
vealed a creatinine of 1.3 mg/dl and albumin of 3.0 g/dl,
unchanged from prior. The patient underwent bilateral lower
extremity Doppler studies, which were negative for DVT. He
received oral cephalexin and oral furosemide without im-
provement. Pemetrexed was discontinued with complete res-
olution of his symptoms. He was not rechallenged.
Case 2
This patient is a 67-year-old woman with metastatic ade-
nocarcinoma of the lung who received 500 mg/m2 pemetrexed.
After her second dose, she developed bilateral lower extremity
edema and erythema. A Doppler study was negative. She did not
receive antibiotics. She was treated with 20 mg prednisone for 5
days, with complete resolution of her symptoms. Pemetrexed
was continued at the same dose. The rash recurred after the sixth
cycle. She was retreated with 20 mg prednisone orally daily for
5 days. Her pemetrexed dose was decreased to 375 mg/m2 with
improvement of her symptoms. It no longer recurred at the lower
pemetrexed dose (Figure 1).
Case Series
We have identified 14 patients who developed bilateral
lower extremity edema and erythema while receiving pem-
etrexed during the past 12 months. In all cases, if pemetrexed
was discontinued, the symptoms resolved.
There were seven men and seven women. Average age
was 72 years. All patients had stage IV adenocarcinoma of
the lung. Pemetrexed was administered every 3 weeks, and
the dose at the onset of the edema and erythema was 500
mg/m2 in eight patients, 400 mg/m2 in one patient, 375
mg/m2 in four patients, and 300 mg/m2 in one patient. Five
patients were receiving single-agent pemetrexed mainte-
nance; the remaining nine patients were receiving combina-
tion chemotherapy (bevacizumab, cisplatinum/carboplati-
num, paclitaxel, or cetuximab.) The edema presented at a
median of eight doses (range, 3–23 doses). In three patients, it
presented after the second to third cycle, in six patients after the
fourth to sixth cycle, in two patients after the 11th to 13th cycle,
and in three patients after the 21st to 23rd cycle. The median
(range) albumin level was 3.0 g/dl (2.3 to 3.7 g/dl). The median
(range) creatinine was 1.2 mg/dl (0.6 to 1.6 mg/dl). Eight
patients were on antihypertensive agents and diuretics. Nearly
all patients (13 of 14 patients) had Doppler ultrasounds of
bilateral lower extremities to rule out DVT. Six patients were
treated with antibiotics for presumed cellulitis. Six patients were
given a diuretic without benefit. Four patients received 20 mg
prednisone daily for 5 days with improvement in both the edema
and erythema. Among these four individuals, when pemetrexed
was given again, pretibial erythema recurred in two. At the time
of recurrence, prednisone was restarted, and the dose of pem-
etrexed was decreased to 375 mg/m2. Eight patients required
discontinuation of pemetrexed because of intolerable peripheral
edema. In five patients, the dose was lowered to control these
symptoms. Thirteen of the 14 patients required the drug to be
stopped or dose lowered.
DISCUSSION
We have collected 14 cases with lung adenocarcinoma
treated with pemetrexed who developed lower extremity
edema and erythema, a condition rarely described.4,5
The most common side effects associated with pem-
etrexed include anemia, neutropenia, renal toxicity, and mac-
ular skin rash. High grade or dose-limiting peripheral edema
related to pemetrexed is rare, and the causative factor is
unknown. Grade 1 or 2 peripheral edema occurred in approx-
FIGURE 1. This is the initial pre-
sentation of the patient’s bilateral
lower extremity edema.
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imately 4.5% of patients who received single-agent pem-
etrexed in a phase III trial in patients with metastatic
NSCLC.6 In these patients, the drug was not discontinued. In
our series, we have identified 14 patients who developed at least
grade 3 lower extremity edema. The edema appeared after as
few as three doses and as many as 23 doses. In all but one case,
the edema and erythema necessitate the drug to be discontinued
or the dose lowered. As pemetrexed is commonly used in the
management of lung adenocarcinoma, understanding the patho-
physiology and its management is necessary.
Docetaxel-associated edema is believed to be related to
a capillary leak syndrome.7 Prophylactic administration of
corticosteroids during treatment with docetaxel has been
noted to decrease the severity of edema. Diuretics are usually
ineffective in managing edema associated with capillary leak
syndrome. This was true in our case series. It is possible that
the pemetrexed-associated edema may be the result of a
capillary leak syndrome and should be managed with addi-
tional corticosteroid administration beyond the routine pro-
phylactic dexamethasone.
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